Advancing structural heart disease care through AI-powered echocardiography
- Featuring
- Featuring
- April 22 2026
- Duration 19: 32
- Published with permission of Cath Lab Digest
In this episode of Cath Lab Conversations, Rebecca Kapur, Managing Editor of Cath Lab Digest, speaks with Dr. Atul Gupta, Chief Medical Officer of Philips Diagnosis and Treatment businesses and a practicing interventional radiologist. Dr. Gupta shares his perspective on the rapid growth of structural heart disease treatment, the evolution of echocardiography hardware and software, and the role of AI in supporting cardiology teams. Dr. Gupta discusses how global healthcare systems are facing converging challenges—an aging and increasingly complex patient population, widespread staff shortages, and shrinking financial resources. He notes that cardiology leaders are increasingly looking to automation and AI to help address these pressures, particularly by reducing variability, improving reproducibility, and supporting efficiency in clinical workflows.
Cath Lab Conversations
Advancements in Structural Heart Disease and AI Are Revolutionizing Echocardiography
At-a-glance:
- Structural heart disease procedures are increasing in volume and complexity, including mitral and tricuspid interventions.
- Rising patient complexity, global staff shortages, and shrinking budgets are driving urgent demand for automation and workflow efficiency.
- AI and automation are being applied to echocardiography to support more consistent and reproducible measurements.
- Advances in echocardiography hardware and miniaturization are expanding patient access and procedural options.
Dr. Gupta highlights how AI‑powered echocardiography is emerging as a pivotal solution. Automation, he notes, improves consistency and reduces the operator‑dependency that has long challenged ultrasound. With FDA‑cleared tools such as 3D auto tricuspid valve quantification and 3D auto color flow quantification for mitral regurgitation, clinicians can obtain faster, more reproducible measurements that match the accuracy of traditional gold standards. These advances are especially critical as structural heart procedures, such as tricuspid interventions, are projected to grow tenfold by 2027.[1]
He also discusses the rising importance of cardio‑oncology, where survivors of cancer face increased risk of heart failure due to cardiotoxic therapies. AI‑driven strain analysis, embedded throughout Philips’ workflow, helps detect early ventricular changes and supports reliable monitoring over time, an essential capability amid global shortages of trained echocardiographers.[2]
Innovation extends beyond software, with hardware breakthroughs such as the mini 3D TEE probe, which is 35% smaller for improved patient comfort and expanded clinical use, and VeriSight Pro intracardiac echo for enhanced visualization during structural heart procedures. Dr. Gupta emphasizes how integrating ultrasound with Philips Azurion image-guided therapy platform enables clinicians to combine x‑ray and echo views for more streamlined, precise, real‑time guidance.
Above all, Dr. Gupta underscores Philips’ commitment to co‑creation with clinicians and hospitals, ensuring innovations—from AI features to probe design—are built around real‑world needs. He closes by expressing optimism about the future of echocardiography and structural heart care, fueled by collaboration, automation, and continuous innovation.
Featuring
Atul Gupta
Copy this URLto share this story with your professional network
Footnotes
- Structural heart devices global market - forecast to 2027. Reportlinker. July 16, 2020. Accessed November 21, 2024.
- United States report. Future Health Index 2024. 9th Ed. Accessed November 21, 2024.
Disclaimer
Results are specific to the institution where they were obtained and may not reflect the results achievable at other institutions. Results in other cases may vary.